Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)
Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)Crystal deal toy celebrating the initial public offering on the Australian Securities Exchange (ASX) of Radiopharm Theranostics. The Sydney-based company develops radiopharmaceutical drugs and treatments for cancer.
(21ALJ553)Lucite deal toy, incorporating a spinning logo, celebrating growth capital provided to New York City-based Click Therapeutics. The debt financing will be used for the commercialization of several therapies, including one aimed at smoking cessation.
(21AKL594)Lucite deal toy celebrating the initial public offering (IPO) of Bluejay Diagnostics. The diagnostics and medical device firm is based in Acton, Massachusetts.
(21AKL655)Lucite tombstone commemorating a capital raise by Aditx Therapeutics (Aditxt). The life sciences and biotech firm is based in Richmond, Virginia.
(21AKL251)Lucite deal tombstone commemorating an agreement for global rights to gout treatment drug ARO-XDH. The agreement was reached between Dublin, Ireland-based Horizon Therapeutics and Arrowhead Pharmaceuticals, headquartered in Pasadena, California.
(21ALJ356)Lucite tombstone celebrating Series B financing for Texas-based biotech firm OncoNano Medicine.
(21ALJ040)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Lucite commemorative celebrating a development and commercialization agreement between Takeda and Arrowhead Pharmaceuticals.
(21ALJ357)
